Dinesh Bhurani

Dinesh Bhurani

Auto-generated profile, based on publicly available information

Dinesh Bhurani

Rajiv Gandhi Cancer Institute & Research Centre

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 May 2018 in Annals of Hematology
Verified
Journal Article
Closed access
PDF file
MAMukul Aggarwal
Mukul Aggarwal
NANarendra Agrawal
Narendra Agrawal
NYNeha Yadav
Neha Yadav
PVPriyanka Verma
Priyanka Verma
RARayaz Ahmed
Rayaz Ahmed
DBDinesh Bhurani
Dinesh Bhurani

12 February 2015 in Mediterranean Journal of Hematology and Infectious Diseases
Verified
Journal Article
Open access
PDF file
JKJyotsna Kapoor
Jyotsna Kapoor
NANarendra Agrawal
Narendra Agrawal
RARayaz Ahmad
Rayaz Ahmad
SSSanjeev Kumar Sharma
Sanjeev Kumar Sharma
AGAnshul Gupta
Anshul Gupta
DBDinesh Bhurani
Dinesh Bhurani
Adherence to imatinib(IM) is of utmost importance in patients with chronic myeloid leukemia(CML) to maximise treatment effectiveness. The main objective is to measure adherence to IM & to evaluate individual patient characteristics, personal, treatment related & psychological factors influencing adherence behaviour. Hundred patients receiving IM were analysed for adherence behaviour using 9 item Morisky Medication Adherence Scale (9-MMAS) . Various factors were assessed for their impact on adherence behaviour. These factors were age, gender, duration of treatment, frequency & dosing of treatment, use of tobacco & alcohol, educational qualification,employment status,monthly income, side effects, financial assistance in treatment, social support, knowledge about medicine & disease, concomitant drug burden, polypharmacy, physician patient interaction, patient educational sessions & prevalence of depression. Seventy five percent of patients were found to be adherent. On univariate analysis, prevalence of depression (p<0.000001), moderate severe depression (p<0.000001), concomitant drug burden (p=0.036) & monthly income (p=0.015) were found to be significantly influencing adherence. The final multivariate model retained prevalence of depression with OR= 10.367 (95% CI, 3.112- 34.538) as independent predictor of adherence to therapy. This study suggests that identification & treatment of depression among CML patients may further enhance adherence to IM therapy.Keywords: Chronic Myeloid Leukemia, Adherence, Imatinib, Nine Item Morisky Medication Adherence Scale, Patient Health Questionnaire -9.

11 February 2022 in Frontiers in Oncology
Verified
Journal Article
Open access
DBDinesh Bhurani
Dinesh Bhurani
RNReena Nair
Reena Nair
SRSenthil Rajappa
Senthil Rajappa
SRSuparna Ajit Rao
Suparna Ajit Rao
NSNithya Sridharan
Nithya Sridharan
RNRamesh Nimmagadda
Ramesh Nimmagadda
Background: Hodgkin’s lymphoma (HL) is one of the most curable malignancies with a 5-year survival of over 80%. Most published literature from low-middle income countries comes from single institute experience. Methodology: The OncoCollect Lymphoma group registry was set up in 2017 and has 9 major participating sites across India. Data of newly diagnosed classical HL (CHL) patients, treated between 2011 and 2017, were collected using OncoCollect software. The clinical features, subtypes, prognostic stratification, treatment patterns, response to first-line treatment, and 5-year outcomes were analyzed. All statistical analysis was done using Microsoft R Open statistical software linked to OncoCollect software. Results: There were 939 newly diagnosed CHL patients with a median age of 38 (range, 18–99) years at presentation. The male-to-female ratio was 2.07:1. Histological subtypes included mixed cellularity, CHL (MC, CHL), nodular sclerosis, CHL (NS, CHL), lymphocyte-rich, CHL (LR, CHL), and lymphocyte-depleted, CHL (LD, CHL), in 60.60%, 26.94%, 9.80%, and 2.66%, respectively. At presentation, 50.43% had B symptoms and 53.35% had advanced disease. 29.71% of advanced-stage patients had high Hodgkin IPI score. 79% and 21% of patients received 1st-line treatment with chemotherapy alone or combined modality treatment with chemotherapy and radiotherapy. The most common first-line chemotherapy was ABVD-based regimen (94.68%). The overall response rate was 93.48%. Complete response rates among early-stage favorable and unfavorable risk groups were 92.73% and 86.79%, and those among advanced-stage low- and high-risk groups were 76.64% and 69.78%, respectively. The median relapse-free follow-up duration was 51 months (IQR 22–69). A significant difference was found in 5-year EFS between the early- and advanced-stage disease 83.53% and 73.55% (p = 0.00087), respectively. Similarly, significant difference was found in EFS among early-stage patients treated with a combination of 4-cycle chemotherapy and radiotherapy vs. chemotherapy alone 88.57% and 66.33% (p = 0.0042), respectively. Conclusions: In this large cohort from India, survival of patients with HL was comparable to the developed world. With a median follow-up of 51 months, the 5-year EFS and OS of all patients were 78.24% and 83.63%, respectively.

26 August 2019 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
SMSumeet Mirgh
Sumeet Mirgh
RARayaz Ahmed
Rayaz Ahmed
NANarendra Agrawal
Narendra Agrawal
VKVishvdeep Khushoo
Vishvdeep Khushoo
AGAmbar Garg
Ambar Garg
DBDinesh Bhurani
Dinesh Bhurani
The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations, reviews, short reports, images in haematology and Letters to the Editor.

26 November 2017 in Transplant Infectious Disease
Verified
Journal Article
Closed access
PDF file
NANarendra Agrawal
Narendra Agrawal
MAMukul Aggarwal
Mukul Aggarwal
JKJyotsna Kapoor
Jyotsna Kapoor
RARayaz Ahmed
Rayaz Ahmed
ASAnjan Shrestha
Anjan Shrestha
DBDinesh Bhurani
Dinesh Bhurani

3 March 2021 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
PGPrasanth Ganesan
Prasanth Ganesan
HJHasmukh Jain
Hasmukh Jain
BBBhausaheb Bagal
Bhausaheb Bagal
PSPapagudi G. Subramanian
Papagudi G. Subramanian
BGBiju George
Biju George
MSManju Sengar
Manju Sengar
The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations, reviews, short reports, images in haematology and Letters to the Editor.